Panama - Inggris - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

dimesol usa, llc. - bicarbonato de sodio - bicarbonato de sodio ....66.0 g/l / cloruro de sodio....23.5 g/l

Panama - Inggris - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

dimesol usa, llc. - bicarbonato de sodio - bicarbonato de sodio ....84.0 g/l

Panama - Inggris - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios baxter, s.a. - bicarbonato de sodio - bicarbonato de sodio ....6.595 g / cloruro de sodio usp....2.353 g

Panama - Inggris - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

dimesol usa, llc. - bicarbonato de sodio - bicarbonato de sodio ....66.0 g/l / cloruro de sodio....23.5 g/l

Panama - Inggris - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

dimesol usa, llc. - bicarbonato de sodio - bicarbonato de sodio ....84.0 g/l

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium bicarbonate, quantity: 8.4 g - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections - 1. metabolic acidosis in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis where a rapid increase in plasma total co2 content is crucial. treatment of metabolic acidosis should be concurrent with measures designed to control the cause of the acidosis. 2.urinary alkalinisation in the treatment of certain drug intoxications (ie barbiturates, salicylates, lithium, methyl alcohol) and in the haemolytic reactions requiring alkalinisation of the urine to diminish nephrotoxicity of blood pigments. urinary alkalinisation is also used in methotrexate therapy to prevent nephrotoxicity. 3.severe diarrhoea which is often accompanied by a significant loss of bicarbonate.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - sodium bicarbonate 8.4%;  ;   - solution for injection - 8.4 % - active: sodium bicarbonate 8.4%     excipient: disodium edetate sodium hydroxide - sodium bicarbonate is used as an alkalinising agent in the treatment of metabolic acidosis which may occur in many conditions including diabetes, starvation, hepatitis, cardiac arrest, shock, severe dehydration, renal insufficiency, severe diarrhoea, addison's disease or administration of acidifying salts (e.g. excessive sodium chloride, calcium chloride, ammonium chloride). sodium bicarbonate is also used to increase urinary ph in order to increase the solubility of certain weak acids (e.g. cystine, sulphonamides, uric acid) and in the treatment of certain intoxications (e.g. methanol, phenobarbitone, salicylates) to decrease renal absorption of the drug or to correct acidosis.

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

international medication systems (uk) ltd - sodium bicarbonate - solution for injection - 8.4 percent weight/volume - electrolyte solutions; sodium bicarbonate

Amerika Serikat - Inggris - NLM (National Library of Medicine)

ajanta pharma usa inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - omeprazole 20 mg - omeprazole and sodium bicarbonate for oral suspension is indicated in adults for the: - short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. - short-term treatment (4 to 8 weeks) of active benign gastric ulcer. - treatment of heartburn and other symptoms associated with gerd for up to 4 weeks. - short-term treatment (4 to 8 weeks) of ee due to acid-mediated gerd which has been diagnosed by endoscopy in adults. the efficacy of omeprazole and sodium bicarbonate for oral suspension used for longer than 8 weeks in patients with ee has not been established. if a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. if there is recurrence of ee or gerd symptoms (e.g., heartburn), additional 4 to 8-week courses of omeprazole and sodium bicarbonate for oral suspension may be considered. - the efficacy of omeprazole and sodium bicarbonate for oral suspension used for longer than 8

Amerika Serikat - Inggris - NLM (National Library of Medicine)

prasco laboratories - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - omeprazole 20 mg - omeprazole/sodium bicarbonate is indicated for short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. [see clinical studies (14.1)] omeprazole/sodium bicarbonate is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. [see clinical studies (14.2)] symptomatic gerd omeprazole/sodium bicarbonate is indicated for the treatment of heartburn and other symptoms associated with gerd for up to 4 weeks. [see clinical studies (14.3)] erosive esophagitis omeprazole/sodium bicarbonate is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy. the efficacy of omeprazole/sodium bicarbonate used for longer than 8 weeks in these patients has not been established. if a patient does not respond to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. if there is recurrence of erosive esophagitis or gerd symptoms (e.g.,